XJP-1, a novel ACEI, with anti-inflammatory properties in HUVECs

Atherosclerosis

Volumn 219, Issue 1, 2011, Pages 40-48

  Fu, Rong ^a   Chen, Zhen ^a   Wang, Qiujuan ^a   Guo, Qinglong ^a   Xu, Jinyi ^a   Wu, Xiaoming ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

8 Dihydroxy 3 methyl isochromanone (XJP 1); Cell adhesion molecules; Endothelin 1 (ET 1); Lipopolysaccharide (LPS); Mitogen activated protein kinases (MAPKs); Monocyte chemotactic protein (MCP) 1; Nitric oxide (NO); Nuclear factor kappa B (NF B); Tumor necrosis factor (TNF )

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 7,8 DIHYDROXY 3 METHYLISOCHROMANONE 4; ANTIINFLAMMATORY AGENT; ATORVASTATIN; BETA ACTIN; BRADYKININ B2 RECEPTOR; CAPTOPRIL; CHEMOATTRACTANT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; XJP 1; ZOFENOPRIL;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CELL ADHESION; CELL NUCLEUS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOPLASM; CYTOTOXICITY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; INFLAMMATION; METABOLITE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS; CHROMONES; ENDOTHELIN-1; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LIPOPOLYSACCHARIDES; MAP KINASE SIGNALING SYSTEM; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; RECEPTOR, BRADYKININ B2; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 80054977120     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.07.010     Document Type: Article

References (34)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340:115-212.
2. Pober J.S. Endothelial activation: intracellular signaling pathways. Arthritis Res 2002, 4:S109-S118.
3. Alon R., Feigelson S. From rolling to arrest on blood vessels: leukocyte tap dancing on endothelial integrin ligands and chemokines at sub-second contacts. Semin Immunol 2002, 14:93-112.
4. Radi Z.A., Kehrli M.E., Ackermann M.R. Cell adhesion molecules, leukocyte trafficking, and strategies to reduce leukocyte infiltration. J Vet Intern Med 2001, 15:516-614.
5. Herman A.G., Moncada S. Therapeutic potential of nitric oxide donors in prevention and treatment of atherosclerosis. Eur Heart J 2005, 26:1945-2011.
6. Liu J., Ren H., Xu J., et al. Total synthesis and antihypertensive activity of (+/-)7,8-dihydroxy-3-methyl-isochromanone-4. Bioorg Med Chem Lett 2009, 19:1822-1823.
7. Xu C.Q., Liu B.J., Wu J.F., et al. Icariin attenuates LPS-induced acute inflammatory responses: involvement of PI3K/Akt and NF-kappaB signaling pathway. Eur J Pharmacol 2010, 642:146-148.
8. Schmitt C.A., Heiss E.H., Dirsch V.M. Effect of resveratrol on endothelial cell function: molecular mechanisms. Biofactors 2010, 36:342-348.
9. Norata G.D., Marchesi P., Passamonti S., et al. Anti-inflammatory and anti-atherogenic effects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice. Atherosclerosis 2007, 191:265-267.
10. de Nigris F., D'Armiento F.P., Somma P., et al. Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice. Int J Cardiol 2001, 81:107-109.
11. Cominacini L., Pasini A., Garbin U., et al. Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am J Hypertens 2002, 15:891-895.
12. Desideri G., Grassi D., Croce G., et al. Different effects of angiotensin converting enzyme inhibitors on endothelin-1 and nitric oxide balance in human vascular endothelial cells: evidence of an oxidant-sensitive pathway. Mediators Inflamm 2008, 2008:305087-305097.
13. Jaffe E.A., Nachman R.L., Becker C.G., et al. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973, 52:2745-2812.
14. Wang M., Zhao X.R., Wang P., et al. Glucose regulated proteins 78 protects insulinoma cells (NIT-1) from death induced by streptozotocin, cytokines or cytotoxic T lymphocytes. Int J Biochem Cell Biol 2007, 39:2076-2077.
15. Park H.J., Jeong S.K., Kim S.R., et al. Resveratrol inhibits Porphyromonas gingivalis lipopolysaccharide-induced endothelial adhesion molecule expression by suppressing NF-kappaB activation. Arch Pharm Res 2009, 32:583-589.
16. De Martin R., Hoeth M., Hofer-Warbinek R., Schmid J.A. The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 2000, 20:e83-e88.
17. Collins T., Read M.A., Neish A.S., et al. Transcriptional regulation of endothelial cell adhesion molecules: NF-κB and cytokine-inducible enhancers. FASEB J 1995, 9:899-909.
18. Bours V., Bonizzi G., Bentires-Alj M., et al. NF-κB activation in response to toxical and therapeutical agents: role in inflammation and cancer treatment. Toxicology 2000, 16:27-38.
19. da Cunha V., Tham D.M., Martin McNulty B., et al. Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis 2005, 178:9.
20. Chung I.M., Kim Y.M., Yoo M.H., et al. Immobilization stress induces endothelial dysfunction by oxidative stress via the activation of the angiotensin II/its type I receptor pathway. Atherosclerosis 2010, 213:109-116.
21. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990. Nature 1993, 362:801-809.
22. Ignarro L.J., Napoli C. Novel features of nitric oxide, endothelial nitric oxide synthase and atherosclerosis. Curr Diab Rep 2005, 5:17-27.
23. Wilcox J.N., Subramanian R.R., Sundell C.L., et al. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol 1997, 7:2479-2510.
24. Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci 2004, 75:639-715.
25. Ma J.S., Kim W.J., Kim J.J., et al. Gold nanoparticles attenuate LPS-induced NO production through the inhibition of NF-kappaB and IFN-beta/STAT1 pathways in RAW264.7 cells. Nitric Oxide 2010, 23:214-216.
26. Steffens S., Mach F. Inflammation and atherosclerosis. Herz 2004, 29:741-748.
27. Zhang H., Park Y., Wu J., et al. Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond) 2009, 116:219-312.
28. Takeya M., Yoshimura T., Leonard E.J., et al. Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody. Hum Pathol 1993, 24:534-536.
29. Gerszten R.E., Mach F., Sauty A., et al. Chemokines, leukocytes, and atherosclerosis. J Lab Clin Med 2000, 136:87-96.
30. Blankenberg S., Barbaux S., Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003, 170:191-213.
31. Poston R.N., Haskard D.O., Coucher J.R., et al. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am J Pathol 1992, 140:665-669.
32. Hajra L., Evans A.I., Chen M., et al. The NF-kappa B signal transduction pathway in aortic endothelial cells is primed for activation in regions predisposed to atherosclerotic lesion formation. Proc Natl Acad Sci U S A 2000, 97:9052-9056.
33. Kempe S., Kestler H., Lasar A., et al. NF-kappa B controls the global pro-inflammatory response in endothelial cells: evidence for the regulation of a pro-atherogenic program. Nucleic Acids Res 2005, 33:5308-5312.
34. Taub D.D. Chemokine-leukocyte interactions. The voodoo that they do so well. Cytokine Growth Factor Rev 1996, 7:355-422.